Inyx launches anti-inflammatory foam for treatment of ulcerative colitis

US manufacturer and developer of specialized drug delivery pharmaceutical products Inyx has completed the supply of an anti-inflammatory foam for launch into the German market for a leading German pharmaceutical manufacturer and distributor.

Its wholly owned UK subsidiary, INyX Pharma, which was acquired in April 2003, has successfully manufactured a non-steroidal anti-inflammatory foam for use in treatment of ulcerative colitis. The product, which acts locally to reduce inflammation, is a metered dose foam that is applied with a rectal applicator.

The foam expands Inyx's participation in the gastroenterological sector of the dermatology market. Non-steroidal anti-inflammatory prescription dermatology products are estimated to account for nearly 15% of the worldwide US$9bn dermatology market. Inyx is one of the few pharmaceutical companies in the world that is equipped to produce pharmaceutical aerosol products in a metered dose foam format. The technological advances, incorporated in the Inyx r&d and production facility in Runcorn in the UK, make possible the manufacture and introduction of new innovative drug delivery systems.

'We are extremely pleased to have established this new relationship with a major European client that uses specialised metered dose anti-inflammatory foams for drug delivery,' said Steven J. Handley, president of Inyx. 'The production volume required for the contract increases the productivity of our new hydrocarbon aerosol line, recently validated to meet European and US regulatory requirements. The new production capability enables us to meet a wide range of product requirements in the foam and mousse dermatological areas.'